These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30980254)

  • 1. Selective antagonism of CRF1 receptor by a substituted pyrimidine.
    Sakellaris S; Matsoukas MT; Karageorgos V; Poulaki S; Kuppast B; Margioris A; Venihaki M; Fahmy H; Liapakis G
    Hormones (Athens); 2019 Jun; 18(2):215-221. PubMed ID: 30980254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.
    Liapakis G; Karageorgos V; Andreadelis I; Holz GG; Dermitzaki E; Kordopati GG; Stylos EΚ; Spyridaki K; Poulaki S; Ntountaniotis D; Sakellaris S; Vanioti M; Kostagianni A; Marousis KD; Leonis G; Kokotos G; Venihaki M; Spyroulias GA; Tselios T; Margioris A; Tzakos AG; Mavromoustakos T
    Amino Acids; 2020 Sep; 52(9):1337-1351. PubMed ID: 32996057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism.
    Spyridaki K; Matsoukas MT; Cordomi A; Gkountelias K; Papadokostaki M; Mavromoustakos T; Logothetis DE; Margioris AN; Pardo L; Liapakis G
    J Biol Chem; 2014 Jul; 289(27):18966-77. PubMed ID: 24838244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
    Islam MR; Markatos C; Pirmettis I; Papadopoulos M; Karageorgos V; Liapakis G; Fahmy H
    Molecules; 2024 Aug; 29(15):. PubMed ID: 39125051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
    Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
    Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.
    Isfort RJ; Wang F; Tscheiner M; Donnelly E; Bauer MB; Lefever F; Hinkle RT; Mazur AW
    J Med Chem; 2005 Jan; 48(1):262-5. PubMed ID: 15634020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
    Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
    J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticotropin Releasing Factor Type 1 and 2 Receptor Signaling in the Medial Prefrontal Cortex Modulates Binge-Like Ethanol Consumption in C57BL/6J Mice.
    Robinson SL; Perez-Heydrich CA; Thiele TE
    Brain Sci; 2019 Jul; 9(7):. PubMed ID: 31330967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, structural optimization, SAR, in silico prediction of physicochemical properties and pharmacological evaluation of novel & potent thiazolo[4,5-d]pyrimidine corticotropin releasing factor (CRF) receptor antagonists.
    Islam MR; Teleb M; Karageorgos V; Sakellaris S; Papadopoulos M; Pirmettis I; Fronczek FR; Liapakis G; Fahmy H
    Eur J Pharm Sci; 2022 Feb; 169():106084. PubMed ID: 34856350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
    Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
    J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
    Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.